Factor VIII levels at 43%, 4 days after infusion
Hypothetical patient and scenario
Factor VIII levels at 43%, 4 days after infusion
Hypothetical patient and scenario
Factor up with an established safety profile
In XTEND-1 and XTEND-Kids, people taking ALTUVIIIO® had:
0
inhibitors
0
serious allergic reaction
Although no inhibitors were found, and no serious allergic reactions occurred in clinical studies, inhibitors and serious allergic reactions are possible with ALTUVIIIO.
In 233 people across both the clinical studies*:
- 15% experienced headache (35 people)
- 13% experienced joint pain (31 people)
- 4% experienced fever (10 people)
- 4% experienced pain in extremities (10 people)
- 4% experienced back pain (9 people)
- 3% experienced vomiting (7 people)
- 15% experienced headache (35 people)
- 13% experienced joint pain (31 people)
- 4% experienced fever (10 people)
- 4% experienced pain in extremities (10 people)
- 4% experienced back pain (9 people)
- 3% experienced vomiting (7 people)
*
Included participants of the XTEND-1 and XTEND-Kids studies.
Find your CoRe Manager and connect today!
Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.